SpyBiotech is a UK-based company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases.
SpyBiotech was spun out of the University of Oxford in 2017. Its proprietary protein superglue technology binds antigens to vaccine delivery platforms in a way which minimises delivery risk and enhances immunogenicity and efficacy.
SpyBiotech has the exclusive rights from the University of Oxford to apply, commercialise and sub-license the SpyTag/SpyCatcher technology in vaccine development.
The company’s current lead candidate is against human cytomegalovirus (HCMV), with clinical studies planned for 2021.
SpyBiotech is supported by high quality investors including Oxford Sciences Innovation (OSI), the capital investor for the University of Oxford, and GV (formally Google Ventures). The company has raised £15 million of funding to date.
SpyBiotech was spun out of the University of Oxford in 2017. Its proprietary protein superglue technology binds antigens to vaccine delivery platforms in a way which minimises delivery risk and enhances immunogenicity and efficacy.
SpyBiotech has the exclusive rights from the University of Oxford to apply, commercialise and sub-license the SpyTag/SpyCatcher technology in vaccine development.
The company’s current lead candidate is against human cytomegalovirus (HCMV), with clinical studies planned for 2021.
SpyBiotech is supported by high quality investors including Oxford Sciences Innovation (OSI), the capital investor for the University of Oxford, and GV (formally Google Ventures). The company has raised £15 million of funding to date.
Location: United Kingdom, England, Oxford
Employees: 11-50
Total raised: $37.52M
Founded date: 2017
Investors 4
| Date | Name | Website |
| - | Oxford Uni... | innovation... |
| - | Oxford Inv... | oxfordinve... |
| - | Oxford Sci... | oxfordscie... |
| - | GV | gv.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 10.02.2021 | Series A | $32.5M | - |
| 30.03.2017 | Seed | $5.02M | GV |
Mentions in press and media 9
| Date | Title | Description |
| 19.11.2021 | Takeda oncology vet drills down the 'basics' at cell therapy startup; Sarepta promotes new R&D chief | Kathryn Corzo Kathryn Corzo — an oncology veteran and the program head behind Sanofi’s multiple myeloma monoclonal antibody isatuximab — is now in the C-suite. The newest member at cell therapy player bit.bio as their... |
| 12.02.2021 | Daily funding roundup - February 11th, 2021 | Zocdoc raised $150M; Modern Health landed $74M; Human Interest secured $55M; WireWheel picks up $20M Zocdoc: Zocdoc is a digital healthcare scheduling platform. Zocdoc has raised $150 million in fresh funding led by Francisco Partners. Read... |
| 10.02.2021 | SpyBiotech raises $32.5M in Series A funding and appoints Lutz B. Giebel as Chairman to support its novel vaccine platform through accelerated clinical development | SpyBiotech has raised $32.5M from leading investors to advance development of its novel “plug and display” vaccine platform technology Braavos Investment Advisers led the round, joined by new investor Oxford Investment Consultants; founding... |
| 10.02.2021 | SpyBiotech Raises $32.5M in Series A Funding | SpyBiotech, a Oxford, United Kingdom-based biotechnology company with a novel vaccine platform technology targeting infectious diseases, cancer and chronic diseases, raised $32.5m in Series A equity financing. The round was led by new inves... |
| 03.04.2017 | Term Sheet — Monday, April 3 | BIG DEAL Hello. Just about every beat at Fortune is enjoying some deal-making action at the moment, so this morning’s Term Sheet is a team effort… Paid Content Securing the enterprise without boundaries From ExtraHop • Why hasn’t VF landed ... |
| 31.03.2017 | SpyBiotech Secures £4m in Seed Funding | SpyBiotech, an Oxford University spinout developing a molecular superglue for rapid development of vaccines targeting a range of diseases, secured £4m in seed funding. The round was led by Oxford Sciences Innovation, the research commercial... |
| 31.03.2017 | Alphabet investment arm GV backs SpyBiotech, an Oxford University spinout working on ‘next-generation’ vaccines | SpyBiotech, a life sciences spinout from the U.K.’s Oxford University, has raised £4 million ($5 million) in seed funding from Oxford Sciences Innovation (OSI) and Alphabet investment arm GV (formerly Google Ventures). As traditional approa... |
| 31.03.2017 | Alphabet investment arm GV backs SpyBiotech, an Oxford University spinout working on ‘next-generation’ vaccines | Did you miss a session from GamesBeat Summit 2022? All sessions are available to stream now. Learn more. SpyBiotech, a life sciences spinout from the U.K.’s Oxford University, has raised £4 million ($5 million) in seed funding from Oxford S... |
| 30.03.2017 | SpyBiotech, which makes a ‘superglue’ for vaccines, raises £4M from GV and Oxford | The startup bug has hit the world of biotechnology, and the latest victim is a business that is building a “super glue,” coincidentally, for bug-combating vaccines. SpyBiotech — a startup spun out of Oxford University that has developed a w... |